Bayer Healthcare to start ADVISE study

Published: 2010-01-28 06:57:00

Updated: 2010-01-28 06:57:00

Bayer Healthcare said it will conduct its phase 4 study entitled “Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension” in the Asia-Pacific region.”

For this study the company will recruit a total of 356 patients in China and Korea. ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK